Drugs / Novel OPV2 candidate 2
Novel OPV2 candidate 2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04544787 | Oct 2018 → Jan 2019 | poliomyelitis | Pierre Van Damme | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novel OPV2 candidate 2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04544787 ↗ |
| Known as | nOPV2 candidate 2 | “This study is designed to evaluate the safety and immunogenicity of two novel type 2 oral poliovirus vaccine (nOPV2) candidates (nOPV2 candidate 1 and nOPV2 candidate 2) in adults.” NCT04544787 ↗ |
| Known as | novel OPV2-c2 | “BACKGROUND: Two novel type 2 oral poliovirus vaccine (OPV2) candidates, novel OPV2-c1 and novel OPV2-c2, designed to be more genetically stable than the licensed Sabin...” PMID 33308429 ↗ Dec 2020 |
| Known as | S2/S15domV/CpG40 | “Live-attenuated serotype-2 poliovirus derived from a modified Sabin type-2 infectious cDNA clone and propagated in Vero cells; candidate 2 (S2/S15domV/CpG40).” NCT04544787 ↗ |
| Modality | Vaccine | “two novel type 2 oral poliovirus vaccine (nOPV2) candidates” NCT04544787 ↗ |
| Route | Oral | “administered orally as six drops (0.3 mL total; approximately 10⁶ CCID50).” NCT04544787 ↗ |